China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

China Pharma Holdings (NYSE American: CPHI) closed its previously announced registered direct offering of 2,500,000 common shares at $2.00 per share, raising gross proceeds of $5.0 million before fees and expenses on July 23, 2026.

Rhea-AI Summary

China Pharma Holdings (NYSE American: CPHI) closed its previously announced registered direct offering of 2,500,000 common shares at $2.00 per share, raising gross proceeds of $5.0 million before fees and expenses on July 23, 2026. According to the company, net proceeds will be used for working capital and general corporate purposes. FT Global Capital acted as exclusive placement agent, and the offering was conducted under an effective Form S-3 shelf registration.

Positive

• $5.0 million gross proceeds raised via registered direct offering
• Capital earmarked for working capital and general corporate purposes
• Financing completed under effective Form S-3 shelf registration

Negative

• Issuance of 2,500,000 new shares implies equity dilution for existing holders
• Net proceeds reduced by placement agent fees and other offering expenses

News Explained

The completed issuance increases China Pharma Holdings’ share count and, absent offsetting changes, reduces existing holders’ percentage ownership.

Argus Jul 24 session 51 alerts

-17.84% close to close 0.3x rel. volume Open Argus

Details

Market move: CPHI -17.84% in the Jul 24 session. registered direct offering

+4.6% Peak Tracked

-35.3% Trough Tracked

$74.97M Market Cap

On Jul 24, the first trading day after this news, CPHI closed 17.84% below the previous close. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -35.3% from its starting point during tracking. Our momentum scanner recorded 51 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 24 session.

Key Figures

Shares Offered: 2,500,000 shares Purchase Price: $2.00 per share Gross Proceeds: $5 million +4 more

Shares Offered

2,500,000 shares

Registered direct offering

Purchase Price

$2.00 per share

Registered direct offering

Gross Proceeds

$5 million

Before placement agent fees and other offering expenses

Use of Proceeds

Net proceeds

Working capital and general corporate purposes

Shelf Filing Date

January 12, 2024

Form S-3 initially filed with the SEC

Shelf Effective Date

February 14, 2024

Form S-3 declared effective by the SEC

Offering Closing Date

July 23, 2026

Offering closed on this date

Previous Offering Reports

2 past events · Latest: Jul 22

Same Type 2 events

1. Jul 22

   Registered direct offering

   24h Move

   -78.9%

   Pricing of 2.5 million shares at $2.00 targeted $5 million gross proceeds.

2. Dec 13

   ATM equity offering

   24h Move

   -4.6%

   ATM offering permitted up to $600,000 in common-stock sales through December 31, 2024.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, shelf registration statement, form s-3, prospectus supplement

4 terms

registered direct offering financial

"announced the closing of its previously announced registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

shelf registration statement regulatory

"The offering was made pursuant to the Company's "shelf" registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement and accompanying base prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIKOU, China, July 23, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced the closing of its previously announced registered direct offering of 2,500,000 shares of the Company's common stock, par value $0.001 per share, at a purchase price of $2.00 per share. The gross proceeds from the offering are $5 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering closed on July 23, 2026.

FT Global Capital, Inc. is acting as the exclusive placement agent for the offering.

The offering was made pursuant to the Company's "shelf" registration statement on Form S-3 (File No. 333-276481) initially filed with the U.S. Securities and Exchange Commission (the "SEC") on January 12, 2024 and declared effective by the SEC on February 14, 2024. A prospectus supplement and accompanying base prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including those regarding China Pharma's Holdings Inc.'s beliefs and expectations about its business strategy, growth outlook, and operational plans are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to: (i) capital and credit market volatility, (ii) local and global economic conditions, (iii) anticipated growth strategies and integration plans, (iv) regulatory changes or governmental approvals, and (v) future business development, operational results, and financial performance of China Pharma Holdings Inc. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. All information provided in this press release is as of the date of this press release, and China Pharma Holdings Inc. undertakes no obligation to update such information, except as required under applicable law.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announces-closing-of-5-0-million-registered-direct-offering-302833767.html

SOURCE China Pharma Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did China Pharma Holdings (CPHI) announce on July 23, 2026 about its offering?

China Pharma Holdings announced the closing of a registered direct offering, issuing 2,500,000 common shares at $2.00 each. According to the company, this generated $5.0 million in gross proceeds before placement agent fees and other offering expenses.

How much money did China Pharma Holdings (CPHI) raise in its July 2026 registered direct offering?

China Pharma Holdings raised $5.0 million in gross proceeds from its July 23, 2026 registered direct offering. According to the company, this came from selling 2,500,000 common shares at $2.00 per share, before deducting fees and expenses.

What is the share price and size of the China Pharma Holdings (CPHI) July 2026 offering?

The offering consisted of 2,500,000 China Pharma Holdings common shares priced at $2.00 per share. According to the company, this registered direct transaction produced $5.0 million in gross proceeds, before placement agent fees and other offering-related expenses are deducted.

How will China Pharma Holdings (CPHI) use the proceeds from its $5 million offering?

China Pharma Holdings plans to use the net proceeds for working capital and general corporate purposes. According to the company, funds from the July 23, 2026 registered direct offering will support its ongoing operational and corporate needs after deducting fees and expenses.

When did the China Pharma Holdings (CPHI) registered direct offering close?

The registered direct offering by China Pharma Holdings closed on July 23, 2026. According to the company, this closing followed its previously announced transaction to sell 2,500,000 common shares at $2.00 per share under an effective Form S-3 shelf registration.

Who acted as placement agent for the China Pharma Holdings (CPHI) July 2026 offering?

FT Global Capital served as the exclusive placement agent for China Pharma Holdings’ July 23, 2026 registered direct offering. According to the company, FT Global Capital handled placement of the 2,500,000 common shares issued at $2.00 per share under the Form S-3 shelf registration.

Was the China Pharma Holdings (CPHI) July 2026 offering made under a shelf registration?

Yes, the July 23, 2026 offering used an effective Form S-3 shelf registration. According to the company, the registration statement (File No. 333-276481) was filed January 12, 2024 and declared effective February 14, 2024, with a prospectus supplement filed and available on the SEC website.